215 related articles for article (PubMed ID: 25502635)
81. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.
Prochazka V; Papajik T; Gazdova J; Divoka M; Rozmanova S; Faber E; Raida L; Kucerova L; Langova K; Jarosova M; Indrak K
Neoplasma; 2011; 58(3):263-70. PubMed ID: 21395368
[TBL] [Abstract][Full Text] [Related]
82. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
Pettengell R; Uddin R; Boumendil A; Johnson R; Metzner B; Martín A; Romejko-Jarosinska J; Bence-Bruckler I; Giri P; Niemann CU; Robinson SP; Kimby E; Schmitz N; Dreger P; Goldstone AH; Montoto S
Bone Marrow Transplant; 2021 Jun; 56(6):1413-1421. PubMed ID: 33452448
[TBL] [Abstract][Full Text] [Related]
83. Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
Sternberg AJ; Matutes E; Killick S; Wotherspoon AC; Catovsky D
Br J Haematol; 1998 Jul; 102(2):532-4. PubMed ID: 9695970
[TBL] [Abstract][Full Text] [Related]
84. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions.
Tarella C; Corradini P; Astolfi M; Bondesan P; Caracciolo D; Cherasco C; Ladetto M; Giaretta F; Ricca I; Vitolo U; Pileri A; Ferrero D
Leukemia; 1999 Sep; 13(9):1456-62. PubMed ID: 10482999
[TBL] [Abstract][Full Text] [Related]
85. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy.
Mercadal S; Pomares H; Sancho JM; Climent F; García O; Encuentra M; Domingo-Doménech E; Sorigué M; Moreno M; Oliveira AC; Ribera JM; Fernández de Sevilla A; González-Barca E
Br J Haematol; 2016 Feb; 172(3):470-3. PubMed ID: 26010479
[No Abstract] [Full Text] [Related]
86. The management of follicular lymphoma.
Lister TA
Ann Oncol; 1991 Feb; 2 Suppl 2():131-5. PubMed ID: 2049310
[No Abstract] [Full Text] [Related]
87. Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma.
Ramaswami R; Pria AD; Parker K; McCann S; Kanfer EJ; Nelson M; Bower M
Bone Marrow Transplant; 2016 Dec; 51(12):1609-1611. PubMed ID: 27595283
[No Abstract] [Full Text] [Related]
88. Angioimmunoblastic T-Cell Lymphoma.
Broccoli A; Zinzani PL
Hematol Oncol Clin North Am; 2017 Apr; 31(2):223-238. PubMed ID: 28340875
[TBL] [Abstract][Full Text] [Related]
89. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Ladetto M; Corradini P; Vallet S; Benedetti F; Vitolo U; Martelli M; Brugiatelli M; Coser P; Perrotti A; Majolino I; Fioritoni G; Morandi S; Musso M; Zambello R; Chisesi T; Di Renzo N; Vivaldi P; De Crescenzo A; Gallamini A; Salvi F; Santini G; Boccomini C; Sorio M; Astolfi M; Drandi D; Pileri A; Tarella C
Blood; 2002 Sep; 100(5):1559-65. PubMed ID: 12176870
[TBL] [Abstract][Full Text] [Related]
90. Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
Weigert O; Dreyling M; Unterhalt M; Hiddemann W; Buske C
Curr Oncol Rep; 2006 Sep; 8(5):368-75. PubMed ID: 16901398
[TBL] [Abstract][Full Text] [Related]
91. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F; Recher C; Milpied N; Gressin R; Salles G; Brice P; Vey N; Haioun C; Colombat P; Rossi JF; Deconinck E; Lazreg F; Bergougnoux L; Delsol G; Attal M
Ann Oncol; 2012 Oct; 23(10):2687-2695. PubMed ID: 22767588
[TBL] [Abstract][Full Text] [Related]
92. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
Ghione P; Palomba ML; Ghesquieres H; Bobillo S; Patel AR; Nahas M; Kanters S; Deighton K; Hatswell A; Ma L; Limbrick-Oldfield EH; Snider JT; Wade SW; Riberio MT; Radford J; Beygi S; Gribben J
Haematologica; 2023 Mar; 108(3):822-832. PubMed ID: 36263843
[TBL] [Abstract][Full Text] [Related]
93. [Classic Hodgkin lymphoma developing early after treatment of follicular lymphoma].
Ueda N; Hashimoto K; Yamazoe Y; Adachi Y; Kihara R; Kuwabara K; Fujino M; Watamoto K
Rinsho Ketsueki; 2020; 61(1):39-43. PubMed ID: 32023601
[TBL] [Abstract][Full Text] [Related]
94. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.
Manna M; Lee-Ying R; Davies G; Stewart C; Oh DH; Peters A; Stewart DA
Leuk Lymphoma; 2019 Jan; 60(1):133-141. PubMed ID: 29966465
[TBL] [Abstract][Full Text] [Related]
95. Allogeneic peripheral blood stem cell transplantation for the treatment of refractory follicular lymphoma.
Masuda R; Teshima T; Ishimaru F; Shinagawa K; Nakayama H; Shimono M; Asakura S; Ohmoto E; Harada M
Intern Med; 1998 Dec; 37(12):1050-4. PubMed ID: 9932640
[TBL] [Abstract][Full Text] [Related]
96. Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
Lazarevic VL; Hägglund H; Remberger M; Wahlin A; Hallböök H; Juliusson G; Kimby E; Malm C; Omar H; Johansson JE
Leuk Lymphoma; 2011 Jan; 52(1):69-71. PubMed ID: 20919855
[No Abstract] [Full Text] [Related]
97. Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.
Okosun J; Montoto S
Hematol Oncol Clin North Am; 2020 Aug; 34(4):701-714. PubMed ID: 32586575
[TBL] [Abstract][Full Text] [Related]
98. Treatment of follicular non-Hodgkin's lymphoma: the old and the new.
Friedberg JW
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S2-6. PubMed ID: 18760706
[TBL] [Abstract][Full Text] [Related]
99. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Rusconi C; Anastasia A; Chiarenza A; Marcheselli L; Cavallo F; Rattotti S; Botto B; Ferrari A; Nassi L; Pagani C; Meli E; Arcaini L; Federico M; Rossi G;
Br J Haematol; 2019 May; 185(4):713-717. PubMed ID: 30793297
[TBL] [Abstract][Full Text] [Related]
100. [Peripheral T-Cell Lymphoma, Not Otherwise Specified Occurring After the Treatment of Relapsed Follicular Lymphoma].
Fukushima H; Inoue T; Ishi N; Okuno T; Son R; Soejima C; Horiuchi M; Ueda H; Yoshida M; Hagihara K; Kanashima H; Nakao T; Yamane T
Rinsho Byori; 2015 Sep; 63(9):1029-34. PubMed ID: 26731890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
